Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.91 -0.35 (-1.62%)
Streaming Delayed Price Updated: 12:55 PM EDT, Jun 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
News headline image
ACADIA Pharmaceuticals's Earnings Outlook ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis ↗
 
Via Benzinga
News headline image
Futures Flat As Yen Discombobulation Extends To Record 13th Day ↗
After some jerky rollercoaster moves in Monday's illiquid trading session, which jerked both higher and lower before closing modestly in the green. 
Via Talk Markets
News headline image
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
News headline image
23 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS... 
Via Benzinga
News headline image
Why Acadia Pharma Shares Are Falling Today ↗
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million. 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
28 Biggest Movers From Yesterday ↗
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
News headline image
Acadia: Helping With Alzheimers And Parkinsons ↗
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia... 
Via Talk Markets
News headline image
Stocks And Oil Drop Following The Weak Job Report ↗
It was a strange day for the market that started with a big miss on the ADP job report. 
Via Talk Markets
News headline image
9 Monster Stock Market Predictions For The Week Of March 28 ↗
It will be a critical week for stocks after weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It may mark the start of a bigger run higher to the... 
Via Talk Markets
News headline image
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today ↗
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision ↗
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results... 
Via Benzinga
News headline image
Expert Ratings For ACADIA Pharmaceuticals ↗
Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks... 
Via Benzinga
News headline image
Recap: ACADIA Pharmaceuticals Q4 Earnings ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis ↗
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.